Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Doctors have alternatives to topical treatments

Doctors have alternatives to topical treatments connected to superbugs

Infectious disease experts this week drew attention to the growing link between topical antibiotic treaments in New Zealand and the superbug MRSA.

Clinical microbiologist Deborah Williamson has stated that “our current use of topical antibiotics is endangering our antibiotic supply and putting lives at risk.”

Founder and Managing Director of AFT Pharmaceuticals, Dr Hartley Atkinson, says he agrees with concerns being voiced by medical professionals that topical antibiotic treatments are used too often, especially amongst children.

Dr Atkinson points out that there are topical applications available through pharmacies that are effective in treating skin infections, but do not carry any risk of antibiotic resistance.

AFT Pharmaceutical’s product Crystaderm® is an example. It contains hydrogen peroxide as an active ingredient for which no bacterial resistance exists. Crystaderm® has wide availability because it is fully funded by PHARMAC on prescription.

According to Dr Atkinson, the need for non-antibiotic topical applications became apparent some years ago.

“The use of fusidic acid products rapidly increased about 15 years ago once mupirocin became prescription only,”2 says Dr Atkinson. “We could see that large-scale use of antibiotic creams and ointments might create future problems from a drug resistance point-of-view. So we wanted to offer people a treatment option that was effective and non-antibiotic. Crystaderm® ticks both boxes.”

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Dr Atkinson acknowledges that competitors might claim he is simply trying to advance sales of Crystaderm® by coming out in support of Dr Williamson.

“Look, they might say that,” says Dr Atkinson. “But frankly, human resistance to antibiotics is a much bigger issue than battles between pharma companies over market share. As a country, we’ve got to address this issue of overuse of antibiotics. Skin infection topical treatments are a good place to start.”

END

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.